Stubborn US inflation has kept interest rate risks in focus, which puts a premium on businesses that can grow through higher costs rather than just endure them. Australian fast growers where insiders own meaningful stakes offer exactly that angle, because management feels the impact of every swing alongside you. This article highlights three such stocks from our high growth, high insider ownership list so you can decide which, if any, deserve a closer look.
The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where insiders have real skin in the game. However, if you want the names that matter most, these 27 high growth high conviction stocks are the strongest companies we’ve found.
PDI Gold (ASX:PDI)
Overview: PDI Gold is a West African gold producer focused on the Kiniéro Gold Mine in Guinea, which drives its growth profile.
Operations: PDI Gold generates about $156 million from Kiniéro and $47 million from Nampala, with Kiniéro contributing the bulk of revenue.
Market Cap: A$4.3 billion
PDI Gold sits neatly in this screener because Kiniéro is not just a development story but an operating mine that already underpins growth, while high insider ownership helps align capital allocation with that production ramp.
“Although Kiniero is ramping strongly with low reported all in sustaining costs and high throughput, the reliance on oxide ore for the next few years means a later shift to harder material could lift unit costs and pressure margins once the current “oxide holiday” ends. This would affect future net margins.”
What really matters for investors is how one future shift in the production mix influences the profit pool Kiniéro can sustain over time.
To see how that production mix could reshape the whole Kiniéro story, read the full narrative for PDI Gold which explains how management plans to support improving returns.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals develops and commercialises precision radiopharmaceutical imaging agents and cancer therapies, with its prostate-focused TLX591 pipeline anchoring its high-growth, insider-backed thesis.
Operations: Telix generates about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, largely tied to US$872 million of sales in the United States.
Market Cap: A$5.3 billion
Telix Pharmaceuticals matters in this fast growing, high insider ownership theme because its cancer radiopharmaceutical toolkit can scale if late-stage programs move from promising data to wider clinical use.
